KDM1A and Alzheimer disease: Of high relevance, Vafidemstat (ORY2001), an oral small molecule that has been optimized for CNS indications and that acts as a covalent inhibitor of LSD1, similar to ORY1001, was shown to reduce neuroinflammation and improve cognitive behavior in animal models of AD and MS 74, 75 as well as to improve inflammation biomarkers in AD patients enrolled in a phase IIa clinical trial 76 (https://clinicaltrials.gov/ct2/show/study/NCT03867253).